Stomatitis

Disease

6 papers3 findings

MeSH D013280

Human trial4
Humans2

Associations

Semaglutide

downin humans1RR 0.378

1 study

Semaglutide is associated with stomatitis in humans (4.0% versus 10.6%; RR 0.378, 95% CI 0.262–0.545).
HumansStem-cell transplant status; propensity-matched comparison with unexposed patientsFrom day 30 after the index event
Semaglutide Exposure and Risk of Oral Mucositis, Systemic Complications, and Mortality After Hematopoietic Stem-Cell Transplantation: A Propensity-Matched Found Data Analysis
Preprints.org6 Oct 2026Preprint

Trial sponsors

Isfahan University of Medical Sciences
1 trialPhase 2/330 people
Second Affiliated Hospital of Nanchang University
1 trialPhase 290 people
Yun-fei Xia
1 trialPhase 290 people
Niels Fristrup
1 trialPhase 284 people
Roswell Park
1 trialPhase 160 people

Latest

3 in 12 months

Preprints.orgYesterday

Semaglutide Exposure and Risk of Oral Mucositis, Systemic Complications, and Mortality After Hematopoietic Stem-Cell Transplantation: A Propensity-Matched Found Data Analysis

Preprint: cohort study of 1,355 peoplePopulations

Paper

Journal of Oral Microbiology30 Sep

T-cell senescence and immunosenescence in chronic oral mucosal inflammatory diseases: mechanisms and therapeutic implications

ReviewCellular senescence

Paper

Alcohol, Clinical & Experimental Research5 Aug

Deciphering the Relationship Between Alcohol Consumption, Oropharyngeal Cancers, and Socioeconomic Determinants

Mendelian randomisation in peoplePopulations

Paper

Lancet17 Dec

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

Randomised trial in 302 peopleLung

Paper

The Lancet Oncology16 Jun

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

Trial in peopleInterventions

Paper

Lancet9 Mar

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

Trial in peopleInterventions

Paper

Lancet14 Nov

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

Trial in peopleInterventions

Paper

The New England Journal of Medicine7 Dec

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Randomised trial in 724 peopleBreast cancer

Paper

Lancet25 Nov

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Randomised trial in 429 peoplemTOR inhibitors

Paper

The New England Journal of Medicine4 Nov

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

Non-randomised trial in 28 peoplemTOR inhibitors

Paper

Stomatitis

Associations

Trial sponsors

Latest

Related